Atlas Trials

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Clinical trial NCT02794883 · COMPLETED

Trial details

NCT number
NCT02794883
Sponsor
Northwestern University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant GliomaRecurrent Glioblastoma
Start date
2016-11-01
Primary completion
2018-05-09
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.